Bionovo is a drug discovery and development company focused on developing safe and effective drugs for the treatment of unmet medical needs in women’s health and cancer.
公司网站：http://www.bionovo.com
Bionovo is a drug discovery and development company focused on developing safe and effective drugs for the treatment of unmet medical needs in women’s health and cancer.
公司网站：http://www.bionovo.com
| 总收入额对比(单位：百万美元) |
| 财季/年份 | 2010 | 2009 | 2008 |
| Q1 | |||
| Q2 | |||
| Q3 | 0.10 | 0.20 | |
| Q4 | 0.10 | 0.20 | |
| 合计 | 0.10 | 0.30 | 0.20 |
| 每股收益对比(单位：美元) |
| 财季/年份 | 2010 | 2009 | 2008 |
| Q1 | -0.22 | -0.31 | -0.26 |
| Q2 | -0.19 | -0.27 | -0.28 |
| Q3 | -0.21 | -0.24 | -0.33 |
| Q4 | -0.18 | -0.23 | |
| 合计 | -0.62 | -1.00 | -1.10 |
| 姓名 | 职务 |
| Isaac Cohen | 董事会主席, CEO, Chief Scientific Officer |
| Mary Tagliaferri M.D. | 总裁, Chief Medical Officer, Treasurer, Secretary, Chief Regulatory Officer, Director |
| Thomas C. Chesterman | CFO, 高级副总裁, Assistant Secretary |
| Michael D. Vanderhoof | Director |
| David Naveh Ph.D. | Independent Director |
| George Butler Ph.D. | Independent Director |
| Louis Drapeau CPA | Independent Director |
| John D. Baxter M.D. | Independent Director |
| 6.03 | +1.02 | +20.36% | |
| 0.32 | +0.036 | +12.56% | |
| 1.75 | +0.17 | +10.76% | |
| 0.54 | +0.04 | +8.0% | |
| 4.30 | +0.27 | +6.7% | |
| 0.76 | +0.047 | +6.65% | |
| 1.01 | +0.06 | +6.32% | |
| 3.88 | +0.18 | +4.86% | |
| 3.22 | +0.12 | +3.87% | |
| 5.67 | +0.21 | +3.85% |
| 开盘价: 0.148 | 当日幅度: 0.116 - 0.15 | 总股本: 5456.00万 | 每股收益: -0.43 | 机构持股: 12.62 | 52周幅度: 0.09 - 1.03 | 每股净资产: 0.21 | 市盈率: |
| 换手率: % | 成交量/平均: 99.21万/155.00万 | 市值: 480.00万 | 股息： |
